CoChat

PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas

Open access
Pascual, Marién, Mena-Varas, María, Robles, Eloy Francisco, Garcia-Barchino, Maria-Jose, Panizo, Carlos, Hervas-Stubbs, Sandra, Alignani, Diego, Sagardoy, Ainara, Martinez-Ferrandis, Jose Ignacio, Bunting, Karen L., Meier, Stephen, Sagaert, Xavier, Bagnara, Davide, Guruceaga, Elizabeth, Blanco, Oscar, Celay, Jon, Martínez-Baztan, Alvaro, Casares, Noelia, Lasarte, Juan José, MacCarthy, Thomas, Melnick, Ari, Martinez-Climent, Jose Angel, Roa, Sergio · 2019 · Blood
Cited by 96

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Refractory or relapsed diffuse large B-cell lymphoma (DLBCL) often associates with the activated B-cell-like (ABC) subtype and genetic alterations that drive constitutive NF-κB activation and impair B-cell terminal differentiation. Here, we show that DNA damage response by p53 is a central mechanism suppressing the pathogenic cooperation of IKK2ca-enforced canonical NF-κB and impaired differentiation resulting from Blimp1 loss in ABC-DLBCL lymphomagenesis. We provide evidences that the interplay between these genetic alterations and the tumor microenvironment select for additional molecular addictions that promote lymphoma progression, including aberrant coexpression of FOXP1 and the B-cell mutagenic enzyme activation-induced deaminase, and immune evasion through major histocompatibility complex class II downregulation, PD-L1 upregulation, and T-cell exhaustion. Consistently, PD-1 blockade cooperated with anti-CD20-mediated B-cell cytotoxicity, promoting extended T-cell reactivation and antitumor specificity that improved long-term overall survival in mice. Our data support a pathogenic cooperation among NF-κB-driven prosurvival, genetic instability, and immune evasion mechanisms in DLBCL and provide preclinical proof of concept for including PD-1/PD-L1 blockade in combinatorial immunotherapy for ABC-DLBCL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2018889931

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 96

Metadata

Authors
Pascual, M., Mena-Varas, M., Robles, E. F., Garcia-Barchino, M.-J., Panizo, C., Hervas-Stubbs, S., Alignani, D., Sagardoy, A., Martinez-Ferrandis, J. I., Bunting, K. L., Meier, S., Sagaert, X., Bagnara, D., Guruceaga, E., Blanco, O., Celay, J., Martínez-Baztan, A., Casares, N., Lasarte, J. J., MacCarthy, T., Melnick, A., Martinez-Climent, J. A., & Roa, S.
Venue
Blood
Published
2019-05-30
Volume
133
Issue
22
Pages
2401-2412
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2936293163
Cited by
96
References
11
FWCI
6.42
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas. https://app.cochat.ai/papers/10.1182/blood.2018889931
The paper
Pascual, M., Mena-Varas, M., Robles, E. F., Garcia-Barchino, M.-J., Panizo, C., Hervas-Stubbs, S., Alignani, D., Sagardoy, A., Martinez-Ferrandis, J. I., Bunting, K. L., Meier, S., Sagaert, X., Bagnara, D., Guruceaga, E., Blanco, O., Celay, J., Martínez-Baztan, A., Casares, N., Lasarte, J. J., . . . Roa, S. (2019). PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas. Blood. https://doi.org/10.1182/blood.2018889931

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.